A new type of bioengineered blood vessel showed strong results in treating severe vascular injuries, potentially offering vascular surgeons a better alternative to synthetic grafts when patients' ...

The FDA on Friday approved acellular tissue engineered vessel (Symvess), an off-the-shelf product for treating vascular trauma in the extremities of adults. The one-time, single-use therapy -- the ...

DURHAM, N.C., July 31, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...

– Post-implantation analysis of ATEVs demonstrates progressive recellularization with host cells, transforming the ATEV into a multi-layered living tissue similar to that of native blood vessels – – ...

The FDA granted a Priority Review in February 2024 and was assigned a PDUFA date of August 10, 2024. ATEV is a bioengineered human tissue designed to be a universally implantable vascular conduit for ...

– Four unique ICD-10-PCS codes, effective October 1, 2024, for replacement of arteries in the upper and lower extremities using Humacyte’s HAV – – BLA submission under Priority Review by FDA for the ...

DURHAM, N.C., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (HUMA), a biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today ...

DURHAM, N.C., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at ...

The FDA approved Humacyte’s lab-grown blood vessel Symvess despite internal warnings from agency scientists about its safety and efficacy, The New York Times reported March 24. The decision, made in ...

– SYMVESS is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial replacement and repair – – In clinical testing SYMVESS was ...